Abstract 136P
Background
Recent studies indicated that Helicobacter pylori (H. pylori) exerts an oncogenic effect on the development of gastric diffuse large B-cell lymphoma (DLBCL). However, the effect of H. pylori status on prognosis of gastric DLBCL remains unconfirmed.
Methods
In the present study, H. pylori status was assessed by histologic examinations, supplemented by results from urease breath test and/or serological analyses where available. Staging tumours included a detailed medical history, physical examination which included peripheral lymph nodes and Waldeyer’s ring, complete hematological biochemical examinations containing serum lactate dehydrogenase (LDH), computed tomography (CT), gastric endoscopy, endoscopic ultrasonography, positron emission tomography (PET)/CT, and bone marrow aspiration and biopsy. Survival curves were estimated by Kaplan-Meier univariate analyses. The prognostic value of H. pylori was verified by both univariate and multivariate analyses.
Results
One hundred and twenty-nine patients diagnosed with primary de novo gastric DLBCL in West China Hospital of Sichuan University were included from 1st January 2009 to 31st May 2016. Over a median follow-up of 45.0 months (range 2-107), mean event-free survival (EFS) was 83.1 months (95% CI 72.7-93.5) and mean overall survival (OS) was 89.9 months (95% CI 80.9-98.9) in patients infected with H. pylori, compared with 62.0 months (95% CI 50.7–73.3) and 72.2 months (95% CI 61.6–82.9), respectively, in H. pylori-negative subgroup (P = 0.010 and P = 0.020 for differences in EFS and OS between groups, respectively). Patients with H. pylori infection had significantly better 5-year EFS and OS than H. pylori-negative subgroup (5-year EFS, 71% vs 47%, P = 0.010; 5-year OS, 79% vs 58%, P = 0.020). Older age, advanced Lugano stage, higher IPI score, and negative H. pylori status were independent negative prognostic indicators of survival outcomes.
Conclusions
H. pylori status in de novo gastric DLBCL can be a promising predictor of disease outcomes, and patients with negative H. pylori status should be followed up carefully since they tend to have a poor outlook.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract